Benefit-Risk Assessment & Pharmacovigilance

All medicines carry a certain level of risk. In this section, you can learn more about how medicines are evaluated to ensure that their benefit outweighs their risk and to ensure that the chances that the medicinal products affect the body in any untended, harmful ways is limited as much as possible. Once medicinal products are approved for the market, pharmacovigilance methods are used to report negative side effects, adverse drug reactions.

 

Webcasts

In this section, you can access a series of webcasts from the EURORDIS Summer School on patient involvement in benefit risk at the European Medicines Agency, how the Pharmaceutical Risk Assessment Committee evaluates medicinal products.

read more...
 

Slideshows

This section contains slide presentations from the EURORDIS Summer School on patient involvement in benefit risk at the European Medicines Agency, how the Pharmaceutical Risk Assessment Committee evaluates medicinal products.

read more...
 

Pharmacovigilance Glossary

A glossary of terms covering topics including adverse reactions and pharmacovigilance

read more...
 
 
The voice of rare disease patients in EuropeEURORDIS The international voice of people living with rare diseases, Rare Diseases International is a EURORDIS initiativeRare Disease International Bringing together patients, families and experts to share experiences in a moderated multilanguage forum, RareConnect is a EURORDIS initiative RareConnect An international awareness raising campaign taking place on the last day of February each year, Rare Disease Day is a EURORDIS initiativeRare Disease Day Join the largest gathering of rare disease stakeholders across Europe, at the biennial European Conference on Rare Diseases and Orphan Products. ECRD is a EURORDIS initiativeEuropean Conference on Rare Diseases